Company Description
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma.
It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025.
The company was incorporated in 2010 and is based in Redwood City, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Nov 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Dennis Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 United States | |
| Phone | 650 649 3530 |
| Website | coherus.com |
Stock Details
| Ticker Symbol | CHRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001512762 |
| CUSIP Number | 19249H103 |
| ISIN Number | US19249H1032 |
| Employer ID | 27-3615821 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dennis M. Lanfear | Chairman, President and Chief Executive Officer |
| Bryan J. McMichael | Chief Financial Officer |
| Carrie Graham | Vice President of Investor Relations and Advocacy |
| Andy Rittenberg | Chief Legal Officer |
| Rebecca Sunshine | Chief Human Resources Officer |
| Michael Chen | Senior Vice President of Commercial Analytics and Trade |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer and Chairman of Scientific Advisory Board |
| Dr. Rosh Dias M.D., MRCP | Chief Medical Officer |
| Arvind Sood | Chief Strategy and Corporate Affairs Officer |
| Sameer Goregaoker | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | ARS | Filing |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 9, 2026 | 10-K | Annual Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 424B5 | Filing |
| Feb 12, 2026 | 424B5 | Filing |